Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
FEMALE
Healthy Volunteers
ID06774209

Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors in Endometrial Cancer

Led by Peking Union Medical College Hospital · Updated on 2025-01-14

30

Participants Needed

1

Research Sites

82 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to explore the use of gallium 68 labeled-fibroblast activation protein inhibitor-04 (68Ga-FAPI-04) Positron Emission Tomography (PET) imaging in women with endometrial cancer. The study compares 68Ga-FAPI-04 PET with other imaging agents to evaluate its advantages in diagnosing this condition. It involves analyzing diagnostic effectiveness by comparing 68Ga-FAPI-04 PET with Fluorine-18 labeled Fluorodeoxyglucose (18F-FDG) PET imaging. Participants undergo three types of imaging examinations: 68Ga-FAPI-04 PET/Computed Tomography (PET/CT), PET/Magnetic Resonance Imaging (PET/MRI), and 18F-FDG PET/CT. The 68Ga-FAPI-04 agent is given intravenously at a dose based on patient weight, followed by whole-body scans 30 to 60 minutes later. The 18F-FDG PET/CT scan is performed within one week before or after the other imaging tests. After imaging, patients have surgical removal of the tumor and suspicious lymph nodes to obtain pathological results. During the study, medical history and necessary laboratory tests are collected. Researchers analyze and compare the diagnostic value of all imaging methods, focusing on tumor size and SUVmax outcomes, tracked over approximately one year. The study monitors patients' diagnostic responses and surgical findings to assess the imaging techniques' effectiveness in endometrial cancer diagnosis and treatment.

CONDITIONS

Official Title

Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors

Who Can Participate

Age: 18Years - 70Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 70 years
  • Willing to provide written informed consent
  • Able to attend follow-up visits
  • Eligible for surgery or biopsy to obtain final pathological results
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Conditions that prevent further diagnosis or treatment due to severity
  • Any contraindications to magnetic resonance imaging (MRI)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

Z

Zhaoxia huang, B.S.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

Phase 0/1 Study of 177Lu-RAD204, a Radiolabeled Antibody Tar...

PDL1 Gene Mutation

Actively Recruiting

5 locations

Study of 177Lu-BetaBart, an Anti-B7-H3 Antibody, for Safety ...

Castration-Resistant Prostate Cancer (CRPC)

Actively Recruiting

4 locations

Evaluation of 18F-T2 PET/CT Imaging for Detecting CAIX Posit...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here